A Randomised, Placebo-Controlled Trial of Erlotinib in Patients With Advanced NSCLC Unsuitable for Chemotherapy.

Trial Profile

A Randomised, Placebo-Controlled Trial of Erlotinib in Patients With Advanced NSCLC Unsuitable for Chemotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jan 2017

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms TOPICAL
  • Most Recent Events

    • 09 Sep 2015 Results assessing values of veriStrat classifier presented at the 16th World Conference on Lung Cancer.
    • 15 Oct 2012 Primary endpoint 'Overall-survival-duration' has not been met.
    • 15 Oct 2012 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top